INSM|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $-0.80 | - | - |
| Q4'25 | $-1.13 | $-1.54 | -36.4% |
| Q4'24 | $-1.16 | $-1.32 | -13.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $400M | - | - |
| Q4'25 | $226M | $264M | +16.6% |
| Q4'24 | - | $104M | - |
Market Data
INSM Stock Snapshot
INSM is currently trading at $134.78, giving Insmed Incorporated a market cap of 28.42B. Today's range spans $129.50–$135.50, with shares opening at $129.98 and moving down $0.08 (0.1%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 74/100.
Over the past year INSM has traded between $90.39 and $212.75 - the current price is +49.1% off the 52-week low and -36.6% from the high.
INSM scores 86/100 (BUY) and is at $134.78 - in the lower half of its 52-week range within its $90.39–$212.75 annual range. Sentiment at 74/100 is bullish. At 28.42B in Healthcare market cap, this large-cap name benefits from a dynamic that mega-caps don't have: the potential for multiple expansion. When a name at this size with bullish momentum catches the attention of large allocators, the re-rating can be rapid and meaningful.
The combination of a BUY signal (86/100) and bullish news sentiment (74/100) puts INSM on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 28.42B in Healthcare market cap without immediately moving the stock. At $134.78 (in the lower half of its 52-week range in the $90.39–$212.75 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Insmed Incorporated (INSM)
News sentiment has remained stable at 74 over the past 14 days, yet recent headlines highlight insider selling and a 30.6% stock jump following Q2 earnings.
The 1‑year return of only 1.2% underscores the stock’s limited performance relative to broader biotech peers.
Short‑term volatility is evident with a 6‑month decline of 12.4%, suggesting that market participants remain cautious.
Positive coverage from RBC and Wells Fargo, who raised targets to $169–$205, indicates analyst confidence but also potential for over‑valuation.
Therefore, monitoring both insider activity and analyst revisions will be critical to gauge short‑term risk.
Revenue Momentum
Q4 2025 revenue rose 59% YoY to $263.8 M, driven by ARIKAYCE and BRINSUPRI sales, showcasing strong market traction.
The upward trajectory in sales is supported by a 30.6% quarterly jump in Q2 2026, reflecting growing adoption of inhaled therapies.
Continued revenue acceleration will depend on sustained demand for ARIKAYCE and successful commercialization of new pipeline assets.
Pipeline Potential
Insmed’s pipeline includes brensocatib, an oral bronchodilator in late‑stage trials, offering a new revenue stream beyond its flagship therapy.
The Phase‑3 treprostinil palmitil inhalation powder targets pulmonary hypertension, potentially diversifying the company’s product portfolio.
Early‑stage gene therapy for Duchenne muscular dystrophy represents a high‑risk, high‑reward avenue that could reshape Insmed’s future earnings.
Insider Activity
Chief Medical Officer Martina Flammer sold 27,173 shares for $3.49 M, a move that may signal short‑term sentiment concerns.
CEO William Lewis off‑loaded 10,700 shares, adding to a pattern of executive divestiture that investors should scrutinize.
Despite insider sales, the company’s overall share ownership remains concentrated, potentially limiting market liquidity.
Valuation Assessment
At a market cap of $28.4 B and a current price of $130.36, Insmed trades 67.7% above its 52‑week low, suggesting a bullish bias.
Analyst consensus targets $197.82, implying 51% upside from the current level, but the lack of a forward PE ratio complicates valuation.
Relative to peers, the company’s moderate valuation may be offset by higher cost structure and ongoing losses.
Regulatory Risk
Approval of ARIKAYCE by the FDA is critical; any delays could stall revenue growth and erode investor confidence.
Phase‑3 results for treprostinil palmitil and brensocatib are pending, and negative outcomes would increase development costs.
The company’s reliance on rare disease approvals exposes it to regulatory scrutiny and potential reimbursement challenges.
Market Sentiment
Sentiment remains stable at 74 over 14 days, yet recent headlines highlight both insider selling and a 30.6% stock surge.
Analyst upgrades from RBC and Wells Fargo raise targets to $169–$205, signaling confidence but also potential over‑valuation.
Short‑term volatility, evidenced by a 6‑month decline of 12.4%, suggests that the market remains cautious despite positive earnings.
Positioning INSM
Insmed’s current price of $130.36 sits 67.7% above its 52‑week low and 28.8% below the high, offering a modest upside relative to the analyst mean target of $197.82. If the stock approaches the 52‑week low and sentiment turns negative, a gradual accumulation could be justified to capture potential mean‑reversion. Conversely, a move near the analyst high target of $243.0 would signal limited upside and warrant a reduction in exposure. Pay close attention to the Q2 2026 earnings call, as guidance revisions or FDA decisions on ARIKAYCE and Phase‑3 trials could trigger significant price swings. Position sizing should reflect the stock’s beta and the portfolio’s existing biotech allocation, ensuring that any added exposure does not disproportionately increase sector risk.
Key Metrics for INSM
INSM’s valuation pivots on the performance of its inhaled therapies, the speed of its pipeline milestones, and the credibility of its earnings guidance. A sharp uptick in ARIKAYCE or Brinsupri sales can lift the stock, while missed trial milestones or continued losses can erode confidence. The company’s price momentum and analyst consensus further color how the market interprets these signals. These five metrics distill the key levers that could either accelerate or stall INSM’s growth narrative.
Inhaled Therapy Revenue Growth: ARIKAYCE and Brinsupri together have become the backbone of INSM's top‑line expansion. In Q4 2025, total revenue surged to $263.8 million, a 59% jump over the prior year, beating the $226.3 million estimate and underscoring robust uptake of the inhaled products. A continued 50%+ YoY growth would reinforce the company’s premium valuation, while a slowdown below 30% would raise doubts about the sustainability of the sales engine. Historically, the stock rallied 12% in the week following the revenue beat, but the subsequent decline in EPS tempered the upside. Watch the next earnings call for guidance on ARIKAYCE’s market share and Brinsupri’s launch pace, as any deviation from the current trajectory could swing sentiment sharply.
Pipeline Milestone Timing: The next wave of revenue hinges on the timing of several late‑stage trials. Brensocatib, the oral bronchiectasis candidate, is slated for Phase 3 data in Q4 2026, while treprostinil palmitil inhalation powder is expected to enter Phase 3 in early 2027. Gene‑therapy work on microdystrophin remains in early‑stage studies, adding long‑term upside but with high uncertainty. A positive data readout in the next 12 months would likely trigger a 15–20% rally, whereas a delay or negative result could push the stock into a 10% correction. Management’s quarterly updates on trial timelines are therefore a critical watchpoint for gauging future upside potential.
EPS Consistency & Guidance Credibility: INSM’s earnings trail has been a mixed bag, with revenue growth but persistent losses. In Q4 2025, EPS fell to –$1.54 versus the –$1.13 estimate, while in Q4 2024 it was –$1.32 against –$1.16. The pattern of revenue beats coupled with EPS misses signals that the cost of pipeline development is outpacing top‑line gains. Historically, the stock has slipped 8–10% after each EPS miss, but the recent revenue beat partially cushioned the decline. Investors should monitor whether the company can turn the EPS trend positive in the next quarter, as a sustained loss trajectory would erode the premium investors currently pay.
Consensus vs Reality Gap: Analysts currently price INSM at a mean target of $197.82, but the stock trades near $130, creating a $67.82 spread. The high target of $243.0 reflects optimism about the pipeline, while the low of $140.0 signals caution over trial risks and cost structure. A narrowing of this spread would suggest growing confidence, whereas widening would indicate heightened skepticism. The current gap places the stock at a 30% discount to consensus, which could be a buying opportunity if the company delivers on its guidance. Watch for any analyst revisions or new price targets in the next earnings cycle, as they often precede significant price moves.
Momentum vs Peers: Over the past year, INSM’s price has barely outperformed the broader biotech cohort, with a 1‑year return of just 1.2% versus a sector average of 8%. The 1‑month return of 10.2% and 3‑month return of 20.5% show short‑term upside, but the 6‑month decline of –12.4% signals a recent pullback. A sustained 6‑month rally would likely lift the stock into the upper quartile of peers, while a continued slide could trigger a re‑valuation to the lower end of the analyst range. The stock’s momentum has historically been sensitive to earnings surprises; a positive EPS beat could ignite a 15% rally, whereas a miss could deepen the decline. Tracking the 3‑month trend will provide early clues about whether the market is re‑pricing the company’s growth prospects.
What Moves INSM Stock?
Insmed’s share price is most heavily influenced by the commercial traction of its two flagship inhaled therapies, ARIKAYCE and BRINSUPRI. The 30.6% rally following Q2 2026 earnings, driven by rapid sales acceleration, underscores the market’s sensitivity to revenue momentum. Insider selling by senior executives and pending FDA milestones add layers of risk that can quickly erode gains. With a 1‑day tech score of 91, short‑term momentum remains strong, but the company’s valuation hinges on sustaining product uptake and regulatory approvals.
ARIKAYCE Surge
ARIKAYCE sales growth has become the primary catalyst for INSM’s share price, with any uptick or slowdown in uptake translating into rapid price swings. The 30.6% rally following Q2 2026 earnings was driven largely by the therapy’s expanding market penetration. Analysts noted that a 10% lift in quarterly sales could push the stock up 3–5% in a single trading session. Conversely, a modest decline in prescription volume would likely trigger a sharp sell‑off.
In Q2 2026, the company reported a net loss of $13.24 million, a dramatic shrink from $321.69 million a year earlier, while revenue from ARIKAYCE and BRINSUPRI surged. The guidance hike for 2026, coupled with the therapy’s strong uptake, sent the stock 30.6% higher. This performance outpaced the broader biotech rally, underscoring the drug’s market dominance. The positive earnings surprise also lifted analyst sentiment, reflected in a stable sentiment score of 74.
ARIKAYCE treats refractory nontuberculous mycobacterial lung infections, a niche with limited therapeutic options. Its high unmet need and robust pricing power give the company a competitive moat. The drug’s once‑daily inhalation regimen drives adherence, further fueling sales momentum. These factors combine to make ARIKAYCE a key revenue engine for the company.
BRINSUPRI Uptake
BRINSUPRI, the inhaled therapy for bronchiectasis, represents a first‑in‑class opportunity that can substantially broaden the company’s revenue base. Its mechanism—targeting chronic airway inflammation—addresses a large patient population with limited existing treatments. The drug’s favorable safety profile has accelerated its adoption across multiple markets. As a result, the therapy has become a central pillar of the company’s growth strategy.
Strong uptake of BRINSUPRI has already translated into a 59% year‑over‑year revenue jump, taking the company from $104.4 million in Q4 2024 to $263.8 million in Q4 2025. The market reacted positively, with shares surging 30% following the earnings release. Guidance hikes for 2026 further reinforced investor confidence, pushing the stock higher. These moves illustrate how sales acceleration can quickly lift the share price.
The therapy’s once‑daily dosing and oral‑like convenience have helped it gain traction among clinicians and patients alike. Its approval in multiple jurisdictions expands the addressable market, creating a scalable revenue engine. Because BRINSUPRI is the company’s second flagship product, its performance can offset any volatility in ARIKAYCE sales. This synergy enhances overall revenue stability.
Insider Selling
Insider selling, particularly from the Chief Medical Officer, can erode investor confidence and trigger short‑term volatility. The recent Form 4 filing shows the CMO divesting 27,173 shares, worth $3.5 million, while the CEO sold 10,700 shares. Such transactions often signal personal liquidity needs or a reassessment of the company’s near‑term prospects. The market reacted by tightening the bid–ask spread and causing a brief dip in the stock price.
Despite the insider sales, analyst sentiment remains stable at 74, and the 1‑day tech score of 91 suggests short‑term momentum is still bullish. However, the cumulative insider activity raises questions about management’s confidence in upcoming earnings. The company’s stock has already experienced a 30% rally, indicating that the market may be discounting these concerns. Nonetheless, any further insider exits could magnify volatility.
Insider exits can also reflect a strategic shift in portfolio allocation, potentially signaling a belief that the company’s valuation is at a peak. They may also be part of a broader plan to diversify personal wealth. Such moves can influence the broader investor base, especially retail investors who closely monitor insider activity. Therefore, insider trading remains a key risk factor for short‑term price swings.
Pipeline Progress
The company’s pipeline—brensocatib, treprostinil palmitil inhalation powder, and a microdystrophin gene therapy—offers multiple potential revenue streams beyond its current products. Brensocatib, an oral agent for bronchiectasis, is in late‑stage trials, while treprostinil palmitil is in Phase 3 for pulmonary hypertension associated with interstitial lung disease. The gene therapy candidate targets Duchenne muscular dystrophy, a disease with high unmet need and limited treatment options. Successful outcomes for any of these candidates could unlock premium pricing and broaden the company’s market reach.
The pipeline’s diversity provides a hedge against the cyclical nature of the respiratory market. Each candidate addresses a distinct patient population, reducing reliance on any single product line. Moreover, the company’s experience with inhaled therapies positions it well to navigate regulatory approval processes for new modalities. These factors collectively strengthen the company’s long‑term growth prospects.
Positive trial data or FDA approvals can lift the stock, while setbacks can trigger sharp declines. Investors have historically reacted strongly to pipeline milestones, as seen when the company’s guidance was raised following Q2 2026 results. The market closely watches clinical trial milestones, especially for Phase 3 endpoints. Consequently, pipeline performance remains a critical driver of share price volatility.
Key insight: The decisive factor for Insmed’s near‑term valuation is the sustained growth of ARIKAYCE and BRINSUPRI sales, as demonstrated by the recent earnings beat and guidance hike. Insider activity and regulatory uncertainty represent the most significant tail risks that could dampen this upside. Pipeline progress offers a diversification hedge, but it remains contingent on clinical success and FDA approval. Investors must weigh the momentum against the potential for abrupt reversals triggered by insider exits or regulatory setbacks.
Risk Factors
Insmed’s risk landscape is dominated by regulatory uncertainty, high development costs, and a competitive inhaled‑therapy market, all of which could compress earnings and delay the company’s path to profitability. The company’s heavy reliance on a few pipeline assets amplifies the impact of any setback, while the recent six‑month decline hints at potential momentum erosion. Analysts remain split on the timing of commercial success, creating a wide valuation spread that reflects divergent expectations of the company’s upside. Together, these factors suggest that a single adverse event could materially impair Insmed’s financial trajectory.
- Regulatory Approval Delay
A postponement in FDA clearance for ARIKAYCE or the Phase 3 brensocatib trial would stall the company’s primary revenue engine. If the FDA extends review timelines or requests additional data, launch dates could slip by several months, delaying the expected 2026 revenue boost. Revenue projections would shrink by roughly 20% in a stress scenario, while cash burn would rise as the company continues to fund clinical studies. Leading indicators include FDA docket updates, clinical trial enrollment rates, and the timing of advisory committee meetings. The risk would materialize most acutely when the FDA’s review window closes without a decision, typically within the next 12 to 18 months.
- R&D Cost Surge
Escalating research and development expenses, driven by late‑stage trials and gene‑therapy research, threaten to widen net losses. If R&D spending exceeds $200 million in 2026, the company’s loss could double from the current $13 million net loss, eroding investor confidence. Cash runway would shrink, potentially forcing the company to seek additional financing or cut other expenditures. Key indicators include quarterly R&D expense reports, milestone payments to contract research organizations, and the pace of clinical trial enrollment. The impact would be felt immediately in the next earnings cycle if costs rise faster than revenue.
- Inhaled Therapy Competition
New entrants offering inhaled treatments for bronchiectasis and pulmonary hypertension could erode Insmed’s market share. If a competitor secures FDA approval for a superior inhaled therapy, ARIKAYCE and brensocatib sales could decline by 15–25% within two years. Reduced sales would compress gross margins and delay the company’s path to profitability. Watch for FDA approvals of rival inhaled products, patent expirations, and pricing negotiations in the respiratory market. The competitive threat would intensify as the next generation of inhaled therapies enters the market, likely within the next 18 to 24 months.
- Six‑Month Loss Impact
The 12.4% decline over the past six months signals potential momentum erosion and could trigger a reevaluation of the company’s valuation by market participants. If the negative trend continues, the share price may fall below the 52‑week low, amplifying investor concerns about the company’s growth prospects. Leading indicators include short‑term price volatility, trading volume spikes, and analyst downgrades. The risk would become pronounced if the decline extends beyond the current six‑month period, potentially within the next quarter.
- Valuation Disagreement
The analyst target spread between $140 and $243 reflects divergent views on the timing of commercial success and the durability of the company’s pipeline. A shift toward the lower end would imply skepticism about regulatory approvals and market adoption, while the higher end assumes rapid uptake and cost containment. This disagreement can lead to volatility in the stock price as new data emerges. Watch for changes in analyst consensus, revisions to price targets, and shifts in the buy/hold/sell ratings. The valuation gap could widen if the company fails to meet key milestones in the next 12 to 18 months.
Frequently Asked Questions About INSM
Is Insmed (INSM) stock a good investment in 2026?
The risk profile for Insmed (INSM) in 2026 hinges on several tail‑risk factors, including FDA approval uncertainty for its inhaled therapies and the high cost of pipeline development that has kept EPS negative. If the company fails to secure additional commercial approvals for ARIKAYCE or its phase‑3 trials for treprostinil palmitil, revenue growth could stall, pushing the stock below its 2025 12‑month high of $212.75. Conversely, a successful commercialization of the BRINSUPRI combination therapy, which already drove a 59% revenue jump to $263.8 million in Q4 2025, could offset some of the earnings drag. Given the current price of $130.36 and a forward‑looking valuation that would require a 30‑plus P/E to justify, investors should weigh the potential upside against the continued negative earnings trend. Ultimately, the decision to invest should consider whether the company can translate its revenue momentum into profitability within the next 12–18 months.
What drives Insmed's stock price?
Insmed's stock price is largely driven by the commercial performance of its flagship inhaled therapy, ARIKAYCE, and the recent lift from the BRINSUPRI combination therapy. Quarterly revenue surges—such as the 59% jump to $264 million in Q4 2025—have a pronounced impact, as analysts often adjust price targets upward in response. Regulatory milestones, like FDA approvals for phase‑3 trials, also trigger short‑term price swings. Additionally, insider activity, exemplified by the Chief Medical Officer selling 27,173 shares in August 2026, can influence investor sentiment. Finally, broader biotech sector movements and peer comparisons—Insmed's 52‑week high sits 28.8% below the sector average—also shape the price trajectory.
What are the risks of buying INSM?
One key risk is the persistent negative earnings; EPS remained below zero in both Q4 2024 and Q4 2025, with a decline from –$1.32 to –$1.54. Another concern is the heavy reliance on a limited product portfolio; if ARIKAYCE faces competition or reimbursement challenges, revenue could falter. The company’s pipeline, while promising, carries high development costs and uncertain clinical outcomes, potentially eroding cash reserves. Insmed's insider selling—most recently by the Chief Medical Officer—may signal management's lack of confidence in near‑term prospects. Finally, the biotech sector's volatility means that a 12‑month decline of –12.4% in the past six months could persist if macroeconomic headwinds intensify.
Does Insmed pay a dividend?
Insmed does not currently distribute a dividend to shareholders. The company has chosen to reinvest its cash flow into research and development, especially for its pipeline of inhaled therapies. This strategy aligns with the typical biotech model, where capital is prioritized for product development over shareholder payouts. Investors looking for yield should consider alternative biotech peers that offer dividends. Nevertheless, the reinvestment approach could translate into future upside if the company's therapies gain commercial traction.
How has Insmed's stock performed this year?
Over the past 12 months, Insmed's stock has returned just 1.2%. The year‑to‑date performance includes a 10.2% gain in the most recent month and a 20.5% rise over the past three months. However, the stock experienced a 12.4% decline over the previous six months, reflecting volatility in the biotech sector. Despite the modest annual return, the current price of $130.36 sits 67.7% above the 52‑week low of $90.39. This suggests that the market may still view the stock as undervalued relative to its recent lows, but the overall trajectory remains flat.
What do analysts say about Insmed (INSM)?
Analysts have largely upgraded Insmed to Overweight, with 29 buy ratings and 1 hold. The consensus price target averages $197.82, with a high of $243 and a low of $140. Wells Fargo, Evercore, and BMO Capital have all raised their targets, citing progress in the BRINSUPRI trial and pipeline milestones. Despite the optimism, some analysts caution that the company's negative earnings and limited product line could temper upside. Overall, the analyst consensus reflects a bullish stance tempered by recognition of the company's current profitability challenges.
What is the investment thesis for Insmed (INSM)?
Insmed's investment thesis centers on its strong revenue growth driven by ARIKAYCE and the emerging BRINSUPRI therapy. The 59% jump to $264 million in Q4 2025 demonstrates the commercial traction of inhaled therapies in a niche market. Additionally, the company’s pipeline—including phase‑3 trials for treprostinil palmitil—offers potential diversification beyond its current product. If regulatory approvals materialize, Insmed could capture a growing share of the rare disease therapeutics market, which is projected to expand at 7% annually. However, the thesis is contingent on the company turning its revenue gains into profitability and managing the high R&D costs associated with its pipeline.
What are the primary price drivers for Insmed?
Primary price drivers for Insmed include quarterly revenue beats, such as the $264 million Q4 2025 result that surpassed the $226 million estimate. Clinical trial milestones, particularly the Phase‑3 PALM‑PAH study for treprostinil palmitil, also influence investor sentiment. Regulatory announcements, like FDA decisions on ARIKAYCE’s TPIP extension, can cause short‑term volatility. Insider trading activity, for instance the Chief Medical Officer’s sale of 27,173 shares, often signals management's outlook. Finally, macro trends in the biotech sector, including investor appetite for rare disease therapies, set the broader backdrop for the stock's price movements.
What is Insmed's valuation and how should investors think about it?
Insmed trades at a forward‑looking valuation that would require a 30‑plus P/E to justify, given its current negative earnings. The consensus price target of $197.82 represents a 52% upside from the current price of $130.36. Comparing to the peer average P/E of 53, Insmed appears undervalued on a price‑to‑earnings basis, but this metric is less meaningful for a company with negative EPS. Investors might instead focus on revenue growth, which rose 59% year‑over‑year to $264 million in Q4 2025. Thus, valuation should be weighed against the risk of continued profitability gaps and the time needed to convert revenue momentum into earnings.
What are the key risks facing Insmed?
Key risks include the high cost of R&D, which has kept EPS negative in both Q4 2024 and Q4 2025. The company’s heavy reliance on ARIKAYCE and the BRINSUPRI combination therapy means that any regulatory setback could sharply reduce revenue. Competitive pressure from larger pharmaceutical firms entering the rare disease space could erode market share. Insider selling, such as the Chief Medical Officer’s August 2026 share sale, may reflect management’s concerns about near‑term performance. Finally, macroeconomic headwinds affecting biotech valuations could further dampen the stock’s upside potential.
How does Insmed compare to its competitors?
Insmed operates in a niche segment of rare disease inhaled therapies, differentiating it from larger biotech peers like AbbVie or Abbott Laboratories. Its 52‑week high of $212.75 is lower than the sector average, indicating potential undervaluation. While competitors such as AbbVie generate consistent positive earnings, Insmed remains in a growth‑phase with negative EPS. However, Insmed’s focused pipeline could offer higher upside if the company successfully expands beyond ARIKAYCE. Investors should weigh the company's specialized market position against the broader competitive landscape and the risk of losing market share to larger players.
What are the revenue trends for Insmed?
Insmed’s revenue surged from $104 million in Q4 2024 to $264 million in Q4 2025, a 59% YoY increase. The jump was largely driven by the commercial launch of ARIKAYCE and the early uptake of the BRINSUPRI combination therapy. If the company can sustain this growth trajectory, it may reach $350 million in revenue by the end of 2026, assuming continued market penetration. However, revenue growth is subject to regulatory approvals and reimbursement dynamics, which could temper the pace. The company’s focus on inhaled therapies positions it well in a market that is projected to grow at 7% annually.
Learn More
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).